The advantages of cell therapy in the treatment of major diseases are increasingly evident! Pudong Innovative Pharmaceutical Enterprises Continuously Make Efforts to Benefit More Patients
In recent years, under the new background of building future industries in the country and Shanghai, Pudong has actively sought and laid out new tracks and directions. Currently, a number of innovative entities have been introduced and gathered in related fields such as targeted drugs, synthetic biology, AI+new drug research and development, new conjugated drugs, new protein degrading drugs, cell drugs, etc...
Tech >>
The advantages of cell therapy in the treatment of major diseases are increasingly evident! Pudong Innovative Pharmaceutical Enterprises Continuously Make Efforts!
In recent years, under the new background of building future industries in the country and Shanghai, Pudong has actively sought and laid out new tracks and directions. Currently, a number of innovative entities have been introduced and gathered in related fields such as targeted drugs, synthetic biology, AI+new drug research and development, new conjugated drugs, new protein degrading drugs, cell drugs, etc...
Tech >>
Shanghai releases a cutting-edge action plan for the biopharmaceutical track, involving gene therapy, medical robots, etc
On the afternoon of October 16th, the Zhangjiang Science Hall opened the 2023 Shanghai International Biopharmaceutical Industry Week. All the pictures in this article were taken by Yu Kai, a journalist from Pengpai NewsOn the afternoon of October 16th, the 2023 Shanghai International Biopharmaceutical Industry Week opened at the Zhangjiang Science Hall...
Tech >>
Death after 8 days of gene therapy, NEJM released the most detailed cause of death based on autopsy reports
In October 2022, a 27 year old patient with Duchenne Muscular Dystrophy (DMD) named Terry Horgan unfortunately passed away after receiving CRISPR gene editing therapy delivered by adeno-associated virus type 9 (AAV9) vector. The exact cause of death was not disclosed at the time, but it raised concerns and doubts about the prospects of CRISPR gene editing therapy...
Tech >>
The 2023 Shanghai International Biomedical Industry Week will open on the 16th, and the action plan for gene therapy and medical robots will be released
Poster journalist Yang Yilin filmed on sitePoster News Reporter Yang Yilin reports from ShanghaiOn October 7th, poster journalists learned from the Shanghai Municipal Government press conference that the 2023 Shanghai International Biopharmaceutical Industry Week will be held from October 16th to 20th.The theme of this Industrial Week is "Joining the Future with Vitality", adhering to the concept of "high-end, distinctive, and international"...
Tech >>
2023 European Liver Annual Conference: Scientific Researchers Commenting on the Prospects of Cisplatin Targeted Immunotherapy AB359
At the first meeting of the European Liver Conference in 2023, Professor Matteo Iannacone from the Scientific Research Institute in Santa Fe, Italy, described AB359, a new preclinical in vivo trial data that further supports AB359 as a promising innovative immunotherapy for treating chronic HBV. The core content of this data is as follows:This study refers to selectively activating the IL-2 pathway in CD8+T cells to drive antiviral activity against hepatitis B virus (HBV)...
Tech >>
Why does gene therapy frequently sell at "skyrocketing prices" with a price of 2.9 million US dollars?
(Tan Qixin, health client reporter of People's Daily, Zhang Shuang) On June 29, the Food and Drug Administration announced that it had approved the listing of Biomarin's gene therapy Roctavian for the treatment of severe type A Haemophilia patients, priced at 2.9 million US dollars...
Tech >>
Huang Ying, CEO of Legendary Biology: Solving the Difficulty of Commercialization of Million CAR-T Therapy
Source of this article: Times Finance Author: Li AohuaDr. Huang Ying, CEO of Legendary Biology...
Tech >>
21CC Cancer Intelligence (Issue 47): Reindeer Bio/Xinda Bio BCMA Targeted CAR-T Therapy Approved for Market Launch; The latest phase 3 test results of AstraZeneca HIMALAYA are positive
21CC(cancercare)2121CC//BCMACAR-T630NMPABBCMACAR-TMM3BCMACAR-TCT103AIBI326BCMACAR-TTCARscFvCD8a4-1BBCD3NMPAFDA/20232FDA/NMPA20226628NMPArepotrectinibROS1Rafael AmadoROS15CDEROS16281ALKNSCLCWX-0593ALK/ROS1ALKALKROS1WX-0593ALKROS1NSCLC180mgIIALK1469.390412056IRCORR67...
Tech >>